BNTC
Benitec Biopharma Inc.
$13.44
+0.24 (+1.82%)
At close · Jul 7
Market Cap
$461.72M
Shares
34,354,334
Earnings calls and other investor events (conferences, investor days) grouped as single events — the transcript and audio, plus, for earnings calls, the 8-K earnings release and the quarter's 10-Q or 10-K, with the reported result and management tone at a glance.
Revenue & result across quarters
Revenue ($B) YoY up YoY down artefacts
LATEST
·
'26 Q3
26-05-14
·
'26 Q2
26-02-12
·
'26 Q1
25-11-14
·
'25 Q3
25-05-14
·
'25 Q2
25-02-14
·
'25 Q1
24-11-14
▼100%
'24 Q4
24-09-26
▼100%
'24 Q3
24-05-13
▼100%
'24 Q2
24-02-13
·
'24 Q1
23-11-13
·
'23 Q4
23-09-21
▲12.5%
'23 Q3
23-05-15
▼44%
'23 Q2
23-02-13
·
'23 Q1
22-11-10
▼100%
'22 Q4
22-09-02
Earnings call
FY26 · Q3
2026-05-14
Benitec Biopharma Inc. Q3 FY2026 Earnings Call
Revenue
$
Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-04-28
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-10
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Ocu
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-09
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-02-23
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-02-12
Benitec Biopharma Inc. Q2 FY2026 Earnings Call
Revenue
$
Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-11-14
Benitec Biopharma Inc. Q1 FY2026 Earnings Call
Revenue
$
Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-09-22
Benitec Biopharma Inc. Q4 FY2025 Earnings Call
Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-05-14
Benitec Biopharma Inc. Q3 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-02-14
Benitec Biopharma Inc. Q2 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-11-14
Benitec Biopharma Inc. Q1 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-09-26
Benitec Biopharma Inc. Q4 FY2024 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-05-13
Benitec Biopharma Inc. Q3 FY2024 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-02-13
Benitec Biopharma Inc. Q2 FY2024 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-2.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-11-13
Benitec Biopharma Inc. Q1 FY2024 Earnings Call
Revenue
$
Diluted EPS
$-3.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-09-21
Benitec Biopharma Inc. Q4 FY2023 Earnings Call
Revenue
$7,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-05-15
Benitec Biopharma Inc. Q3 FY2023 Earnings Call
Revenue
$54,000
▲ 12.5% YoY Diluted EPS
$-2.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-02-13
Benitec Biopharma Inc. Q2 FY2023 Earnings Call
Revenue
$14,000
▼ 44% YoY Diluted EPS
$-3.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-11-10
Benitec Biopharma Inc. Q1 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-7.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-09-02
Benitec Biopharma Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-05-16
Benitec Biopharma Inc. Q3 FY2022 Earnings Call
Revenue
$48,000
▲ 4700% YoY Diluted EPS
$-6.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-02-14
Benitec Biopharma Inc. Q2 FY2022 Earnings Call
Revenue
$25,000
▲ 2400% YoY Diluted EPS
$-10.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-11-15
Benitec Biopharma Inc. Q1 FY2022 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-10.54
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-09-20
Benitec Biopharma Inc. Q4 FY2021 Earnings Call
Revenue
$2,000*
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q4
2020-09-23
Benitec Biopharma Inc. Q4 FY2020 Earnings Call
Revenue
$*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls